Summary

Point Of Care Diagnostics Market Growth & Trends

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their need for accessible home-based care are anticipated to drive the market.

The adoption of POCT in emerging economies such as Africa and Latin America is anticipated to be a growth determinant of the global POCT market. The authorities are decentralizing the healthcare system and increasing their investments. For instance, the African regulations in Kenya allotted USD 346.7 to Managed Equipment Services project for the government's initiative toward modernizing facilities by procuring new equipment. The Ministry of Health selected GE Health and Philips to offer equipment across 47 countries. Similarly, Latin America decentralized IVD testing, which encourages private players to take strategic initiatives to meet the region’s existing demand for affordable POCT, especially in the infectious diseases segment.

Currently developed POC devices and tests are employed across different medical diagnostic applications, including cancer, pregnancy, and infectious diseases. Patients and physicians employ POC tests to screen conditions, confirm diagnoses, and design suitable therapeutic approaches based on patient health. However, the enthusiasm displayed by different consumers, such as doctors, patients, and caregivers, varies widely. This dynamic consumption pattern of POC diagnostic products is also attributed to economic scalability, financial interests, and lack of a universal healthcare structure.

In the light of COVID-19, the lockdown imposed across the globe has necessitated virtual visits and rapid diagnostic tests that assist patients to avoid hospital visits. Post-lockdown, the eHealth strategy is the emerging area of priority and investment such as an automated patient appointment system, lab result transmission system, healthcare workers' communication system, and medical products procurement system for the companies and governments. It is anticipated to continue to prioritize home-based healthcare delivery even after the pandemic, especially for patients with pre-existing conditions. For instance, NeuroMetrix, Inc. appointed a team to develop the business of DPNCheck, a POCT for peripheral neuropathies. The team is responsible for expanding the footprint in the healthcare market and focusing on the Medicare Advantage population.

Point Of Care Diagnostics Market Report Highlights

• The Infectious disease led the market and accounted for 27.8% of global revenue share in 2023. Growth of the segment is attributed to increasing demand for rapid tests, which has encouraged industry players to deliver point of care solutions to decentralized regions and launch innovative solutions.

• Home sector is projected to witness the highest growth rate over the forecast period owing to the comfort level and cost-effectiveness of point of care diagnostics provided to patients at home. POCT devices are easy to use and do not, mandatorily, require any modern lab infrastructure for testing simpler target analytes in a patient's sample

• North America dominated the market and accounted for a 42.9% share in 2023 owing to the increasing demand for new technologies, a large pool of key players, and advanced healthcare infrastructure

• The Asia Pacific is anticipated to witness significant growth in the market owing to the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases. The increasing population with limited disposable income is the potential target market for the key players in the region

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Point Of Care Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Introduction of CLIA waived tests
3.2.1.2. Rise in funding from government and private institutions
3.2.1.3. Growing geriatric population base
3.2.1.4. Growing prevalence of target diseases
3.2.1.5. Growing demand for home healthcare and the introduction of advance technology enabled products
3.2.2. Market restraint analysis
3.2.2.1. High procedure costs coupled with limited adoption of POC devices in certain emerging regions
3.2.2.2. Presence of ambiguous regulatory as well as reimbursement frame work for primary care setting
3.2.3. Market challenge analysis
3.2.3.1. POC device pose challenges in maintaining the quality standards
3.2.4. Market opportunity analysis
3.2.4.1. Networking & remote integration of POC diagnostics products
3.2.4.1.1. Smartphone orientation
3.2.4.1.2. Embedded vision based solutions
3.2.4.1.3. Digital technologies
3.3. Point Of Care Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis, By Product
3.4.1. Glucose Testing
3.4.2. Hb1Ac Testing
3.4.3. Coagulation Testing
3.4.4. Fertility/Pregnancy
3.4.5. Infectious Disease
3.4.6. HIV POC
3.4.7. Clostridium Difficile POC
3.4.8. HBV POC
3.4.9. Pneumonia or Streptococcus Associated Infections
3.4.10. Respiratory Syncytial Virus (RSV) POC
3.4.11. HPV POC
3.4.12. Influenza/Flu POC
3.4.13. HCV POC
3.4.14. MRSA POC
3.4.15. TB and Drug-resistant TB POC
3.4.16. HSV POC
3.4.17. COVID-19
3.4.18. Other Infectious Diseases
3.4.19. Cardiac Markers
3.4.20. Thyroid Stimulating Hormone
3.4.21. Hematology
3.4.22. Primary Care Systems
3.4.23. Decentralized Clinical Chemistry
3.4.24. Feces
3.4.25. Lipid Testing
3.4.26. Cancer Marker
3.4.27. Blood Gas/Electrolytes
3.4.28. Ambulatory Chemistry
3.4.29. Drug of Abuse (DOA) Testing
3.4.30. Autoimmune Diseases
3.4.31. Urinalysis/Nephrology
Chapter 4. Point Of Care Diagnostics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Point Of Care Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Glucose Testing
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Hb1Ac Testing
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Coagulation Testing
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Fertility/Pregnancy Testing
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Infectious Disease
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.2. HIV POC
4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.3. Clostridium Difficile POC
4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.4. HBV POC
4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.5. Pneumonia or Streptococcus Associated Infections
4.4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.6. Respiratory Syncytial Virus (RSV) POC
4.4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.7. HPV POC
4.4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.8. Influenza/Flu POC
4.4.5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.9. HCV POC
4.4.5.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.10. MRSA POC
4.4.5.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.11. TB and drug resistant TB POC
4.4.5.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.12. HSV POC
4.4.5.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.13. COVID-19
4.4.5.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.14. Other infectious diseases
4.4.5.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.6. Cardiac Markers
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.7. Thyroid Stimulating Hormone
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.8. Hematology
4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.9. Primary Care Systems
4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.10. Decentralized Clinical Chemistry
4.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.11. Feces
4.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.12. Lipid Testing
4.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.13. Cancer Marker
4.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.14. Blood Gas/Electrolytes
4.4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.15. Ambulatory Chemistry
4.4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.16. Drug of Abuse (DOA) Testing
4.4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.17. Autoimmune diseases
4.4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.18. Urinalysis/Nephrology
4.4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Point Of Care Diagnostics Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Point Of Care Diagnostics Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Clinics
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
5.4.1.2. Pharmacy & Retail Clinics
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.3. Physician Office
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.4. Urgent Care Clinics
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.5. Non-practice Clinics
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Hospitals
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. Home
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. Assisted Living Healthcare Facilitates
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Laboratory
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. Point Of Care Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Europe
6.6.1. Germany
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. UK
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.6. Russia
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Russia market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.7. Norway
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.8. Sweden
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.9. Denmark
6.6.9.1. Key country dynamics
6.6.9.2. Regulatory framework/ reimbursement structure
6.6.9.3. Competitive scenario
6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. South Korea
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.5. Australia
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.1.1. Abbott
7.3.1.2. Alere Inc.
7.3.1.3. F. Hoffmann-La Roche Ltd.
7.3.1.4. Siemens Healthcare GmbH
7.3.1.5. Danaher Corporation
7.3.1.6. Werfen
7.3.1.7. BD
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Company Profiles
7.3.4.1. F. Hoffmann-La Roche Ltd.
7.3.4.1.1. Company overview
7.3.4.1.2. Financial performance
7.3.4.1.3. Product benchmarking
7.3.4.1.4. Strategic initiatives
7.3.4.2. Qiagen
7.3.4.2.1. Company overview
7.3.4.2.2. Financial performance
7.3.4.2.3. Product benchmarking
7.3.4.2.4. Strategic initiatives
7.3.4.3. Danaher Corporation
7.3.4.3.1. Company overview
7.3.4.3.2. Financial performance
7.3.4.3.3. Product benchmarking
7.3.4.3.4. Strategic initiatives
7.3.4.4. Becton Dickinson (BD)
7.3.4.4.1. Company overview
7.3.4.4.2. Financial performance
7.3.4.4.3. Product benchmarking
7.3.4.4.4. Strategic initiatives
7.3.4.5. bioMérieux
7.3.4.5.1. Company overview
7.3.4.5.2. Financial performance
7.3.4.5.3. Product benchmarking
7.3.4.5.4. Strategic initiatives
7.3.4.6. Abbott
7.3.4.6.1. Company overview
7.3.4.6.2. Financial performance
7.3.4.6.3. Product benchmarking
7.3.4.6.4. Strategic initiatives
7.3.4.7. Siemens Healthcare GmbH
7.3.4.7.1. Company overview
7.3.4.7.2. Financial performance
7.3.4.7.3. Product benchmarking
7.3.4.7.4. Strategic initiatives
7.3.4.8. Werfen
7.3.4.8.1. Company overview
7.3.4.8.2. Financial performance
7.3.4.8.3. Product benchmarking
7.3.4.8.4. Strategic initiatives
7.3.4.9. Nova Biomedical
7.3.4.9.1. Company overview
7.3.4.9.2. Financial performance
7.3.4.9.3. Product benchmarking
7.3.4.9.4. Strategic initiatives
7.3.4.10. Trividia Health, Inc.
7.3.4.10.1. Company overview
7.3.4.10.2. Financial performance
7.3.4.10.3. Product benchmarking
7.3.4.10.4. Strategic initiatives
7.3.4.11. QuidelOrtho Corporation
7.3.4.11.1. Company overview
7.3.4.11.2. Financial performance
7.3.4.11.3. Product benchmarking
7.3.4.11.4. Strategic initiatives
7.3.4.12. Trinity Biotech
7.3.4.12.1. Company overview
7.3.4.12.2. Financial performance
7.3.4.12.3. Product benchmarking
7.3.4.12.4. Strategic initiatives
7.3.4.13. Sekisui Diagnostics
7.3.4.13.1. Company overview
7.3.4.13.2. Financial performance
7.3.4.13.3. Product benchmarking
7.3.4.13.4. Strategic initiatives
7.3.4.14. Orasure Technologies, Inc.
7.3.4.14.1. Company overview
7.3.4.14.2. Financial performance
7.3.4.14.3. Product benchmarking
7.3.4.14.4. Strategic initiatives
7.3.4.15. Spectral Medical, Inc.
7.3.4.15.1. Company overview
7.3.4.15.2. Financial performance
7.3.4.15.3. Product benchmarking
7.3.4.15.4. Strategic initiatives
7.3.4.16. EKF Diagnostics Holdings plc.
7.3.4.16.1. Company overview
7.3.4.16.2. Financial performance
7.3.4.16.3. Product benchmarking
7.3.4.16.4. Strategic initiatives
7.3.4.17. Anbio Biotechnology Co., Ltd.
7.3.4.17.1. Company overview
7.3.4.17.2. Financial performance
7.3.4.17.3. Product benchmarking
7.3.4.17.4. Strategic initiatives
7.3.4.18. AccuBioTech Co., Ltd
7.3.4.18.1. Company overview
7.3.4.18.2. Financial performance
7.3.4.18.3. Product benchmarking
7.3.4.18.4. Strategic initiatives
7.3.4.19. ALPHA LABORATORIES
7.3.4.19.1. Company overview
7.3.4.19.2. Financial performance
7.3.4.19.3. Product benchmarking
7.3.4.19.4. Strategic initiatives
7.3.5. Company Market Positioning Analysis, 2023
7.3.5.1. Glucose Monitoring
7.3.5.2. Cardiac Markers
7.3.5.3. Hematology
7.3.5.4. Coagulation
7.3.5.5. Fertility Testing
7.3.5.6. Infectious Diseases
7.3.5.7. Decentralized Clinical Chemistry
7.3.5.8. Oncology Markers
7.3.5.9. Blood Gas Testing
7.3.5.10. Ambulatory Testing
7.3.5.11. Drug of Abuse
7.3.5.12. Urinalysis
7.3.6. Key Parameters
7.3.6.1. Company Size
7.3.6.2. Geographic Presence
7.3.6.3. Production Portfolio
7.3.6.4. Collaborations
7.3.7. Market Differentiators
7.3.7.1. Application Trends
7.3.7.2. Technology Trends
7.3.7.3. Test Location Trends
7.3.7.4. End-use Trends
7.3.7.5. Regional Trends
7.3.8. Private Companies
7.3.8.1. New Entrants/Emerging Players
7.3.9. Regional Mapping: Public and Private Companies
Chapter 8. Conclusion